Since the introduction of multigene assays, use of the 21-gene RS test in clinical practice has gradually increased and is anticipated to be widely utilized as a treatment decision aid in ER-positive and HER2-negative early-stage breast cancer patients [16, 17]. This evidence concerns the gene ERBB2 and breast cancer.